Blue Trust Inc. Buys 6,174 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Blue Trust Inc. grew its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 3,041.4% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 6,377 shares of the biotechnology company’s stock after buying an additional 6,174 shares during the period. Blue Trust Inc.’s holdings in Aurinia Pharmaceuticals were worth $57,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in AUPH. FMR LLC increased its holdings in shares of Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after buying an additional 3,919 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $108,000. China Universal Asset Management Co. Ltd. increased its holdings in Aurinia Pharmaceuticals by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 10,700 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $248,000. Finally, BNP Paribas Financial Markets raised its position in Aurinia Pharmaceuticals by 172.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 20,324 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Aurinia Pharmaceuticals Trading Down 0.2 %

Aurinia Pharmaceuticals stock opened at $8.03 on Wednesday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -53.53 and a beta of 1.22. The firm has a 50-day moving average of $8.27 and a 200-day moving average of $7.75. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a one year low of $4.71 and a one year high of $10.67.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.